The CAV2 Knockout A2780 Polyclonal Cells are a CRISPR/Cas9-edited polyclonal population derived from A2780 human ovarian carcinoma cells, designed for CAV2 loss-of-function studies. This mixed knockout pool, generated by Cas9-mediated gene disruption without clonal isolation, preserves the parental line??s genetic background while enabling interrogation of caveolin-2-dependent processes in ovarian cancer. As a polyclonal product, it circumvents clonal bias and captures diverse edited alleles, providing a robust model for caveolae biology.
A2780 is a widely used ovarian carcinoma cell line derived from an untreated patient, retaining key oncogenic signaling pathways and tumorigenic properties. Its epithelial origin and hormonal responsiveness make it a benchmark for ovarian cancer research, including studies on drug sensitivity, metastasis, and tumor microenvironment interactions. The CAV2 knockout derivative leverages this well-characterized background to specifically assess how caveolin-2 contributes to ovarian cancer cell behavior and caveolae-dependent processes.
Caveolin-2, together with caveolin-1 and the cavin-1/PTRF coat complex, forms the structural core of caveolae, plasma membrane invaginations essential for endocytosis, signal compartmentalization, and lipid regulation. It is regulated by upstream factors such as EGF, insulin, SRC kinase, protein kinase C, and cholesterol, and physically interfaces with integrins, SRC family kinases, and G-protein alpha subunits. Downstream, caveolae modulate receptor tyrosine kinases like EGFR, the MAPK/ERK cascade (ERK1/2), STAT3, RhoA, and eNOS. CAV2 knockout thus perturbs multiple signaling hubs, impairing cell adhesion, proliferation, and transcriptional responses.
In ovarian cancer, CAV2 knockout compromises caveolae integrity, reducing surface integrins and attenuating ERK1/2 and STAT3 activation, thereby suppressing migration, invasion, and anchorage-independent growth. This model captures caveolar dysfunction, enabling study of CAV2??s role in tumor progression and drug uptake via caveolae-mediated endocytosis, with translational relevance.
Applications include western blotting for caveolin-2, immunofluorescence for caveolae, migration/invasion assays, proliferation measurements, co-IP of caveolin-1/2, phospho-ERK analysis, cholesterol depletion/repletion, flow cytometry for integrins, and RT-qPCR for CAV2. These cells facilitate investigation of CAV2 signaling, therapeutic targeting, and microenvironment interactions. For more information, contact Ascent Research.
